Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedPage revision updated from v3.3.3 to v3.3.4, a minor metadata change with no visible impact on content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedExpanded the study's Locations section with a wide array of new sites across multiple countries and regions (examples include Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Japan, Mexico, the Netherlands, Spain, the United Kingdom, and the United States).SummaryDifference3%

- Check51 days agoChange DetectedNon-significant editorial updates were made: the page now explains that publications are automatically filled from PubMed and the revision was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedDeleted the generic government funding operating status notice from the page. The study content, eligibility criteria, and contacts remain unchanged.SummaryDifference0.1%

- Check66 days agoChange DetectedThe Locations section now lists 'Tainan, Taiwan, 704' and 'Tainan, Taiwan, 73657', replacing 'Tainan City, Taiwan, 704' and 'Tainan City, Taiwan, 73657'.SummaryDifference0.0%

- Check80 days agoChange DetectedNo additions or deletions were detected on the Study Details page for NCT04194944 LIBRETTO-431; core content such as the Study Title, design, interventions, primary and secondary outcomes, eligibility criteria, and Locations remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.